| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8441051 | European Journal of Cancer | 2016 | 9 Pages |
Abstract
Dalotuzumab was well tolerated in paediatric patients with advanced solid malignancies. The RP2D of dalotuzumab is 900Â mg/m2 (ClinicalTrials.gov identifier: NCT01431547, Protocol PN062).
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Didier Frappaz, Sara M. Federico, Andrew D.J. Pearson, Lia Gore, Margaret E. Macy, Steven G. DuBois, Isabelle Aerts, Robert Iannone, Ryan Geschwindt, Arne Van Schanke, Rui Wang, Birgit Geoerger,